APA

Schmitt M., Harbeck N., Brünner N., Jänicke F., Meisner C., Mühlenweg B., Jansen H., Dorn J., Nitz U., Kantelhardt E. J. & Thomssen C. (20111025). Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. : Expert review of molecular diagnostics.

Chicago

Schmitt Manfred, Harbeck Nadia, Brünner Nils, Jänicke Fritz, Meisner Christoph, Mühlenweg Bernd, Jansen Heike, Dorn Julia, Nitz Ulrike, Kantelhardt Eva J and Thomssen Christoph. 20111025. Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. : Expert review of molecular diagnostics.

Harvard

Schmitt M., Harbeck N., Brünner N., Jänicke F., Meisner C., Mühlenweg B., Jansen H., Dorn J., Nitz U., Kantelhardt E. J. and Thomssen C. (20111025). Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. : Expert review of molecular diagnostics.

MLA

Schmitt Manfred, Harbeck Nadia, Brünner Nils, Jänicke Fritz, Meisner Christoph, Mühlenweg Bernd, Jansen Heike, Dorn Julia, Nitz Ulrike, Kantelhardt Eva J and Thomssen Christoph. Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. : Expert review of molecular diagnostics. 20111025.